Anti-nociceptive tolerance to opioids is a well-described phenomenon, which severely limits the clinical efficacy of opioids for the treatment of chronic pain syndromes. The mechanisms that drive anti-nociceptive tolerance, however, are less well understood. We have previously shown that glia have a central role in the development of morphine tolerance and that administration of a glial modulating agent attenuated tolerance formation. Recently, we have demonstrated that morphine enhances microglial Iba1 expression and P2X4 receptor-mediated microglial migration via direct l opioid receptor signaling in in vitro microglial cultures. We hypothesize that P2X4 receptors drive morphine tolerance and modulate morphineinduced spinal glial reactivity. Additionally, we hypothesize that perivascular microglia play a role in morphine tolerance and that P2X4 receptor expression regulates perivascular microglia ED2 expression. To test these hypotheses, rats were implanted with osmotic minipumps releasing morphine or saline subcutaneously for seven days. Beginning three days prior to morphine treatment, P2X4 receptor antisense oligonucleotide (asODN) was injected intrathecally daily, to selectively inhibit P2X4 receptor expression. P2X4 receptor asODN treatment inhibited morphine-induced P2X4 receptor expression and blocked anti-nociceptive tolerance to systemically administered morphine. P2X4 receptor asODN treatment also attenuated the morphine-dependent increase of spinal ionized calcium binding protein (Iba1), glial fibrillary acidic protein (GFAP) and l opioid receptor protein expression. Chronic morphine also decreased perivascular microglial ED2 expression, which was reversed by P2X4 receptor asODN. Together, these data suggest that modulation of P2X4 receptor expression on microglia and perivascular microglia may prove an attractive target for adjuvant therapy to attenuate opioid-induced anti-nociceptive tolerance.
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Introduction
Opioids are the mainstay of acute pain management; however, their use in the treatment of chronic pain is limited primarily by poor efficacy, untoward side-effects and anti-nociceptive tolerance. Historically, opioid tolerance research has focused on neuronal mechanisms of adaptation and sensitization. Recently, our laboratory, among others, has begun to investigate the critical role of glia in morphine tolerance [30, 42] .
We have previously reported that morphine administration produces robust microglial and astrocytic changes, as evidenced by increased cellular hypertrophy and microglial CD11b, Iba1 expression and astrocytic GFAP expression both in vitro Perivascular microglia are a subtype of microglia which closely appose astrocytes and endothelial cells surrounding CNS vasculature and express ED2, a molecule associated with anti-inflammatory processes [10, 56] . We have previously shown that ED2 expression is reduced following L5 spinal nerve transection and that a cannabinoid receptor 2 agonist enhanced spinal ED2 expression and inhibited tactile allodynia [36] . These results suggest that ED2 expressing perivascular microglia may have a role in the resolution of insult to the CNS.
Building upon our prior in vivo findings, we recently reported the effects of morphine on in vitro microglial migration, Iba1 and
